Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing/Beijing, 100010, China
Location contact
Meng-Tong Zang, MD
CONTACT
Xiao-Hui Zhang, Professor
CONTACT
NCT Number: NCT06531525
To evaluate whether low molecular heparin could improve pregnancy outcomes in pregnancies with protein S deficiency.
Trial opening soon.
Get Notified18 year–50 year
Female
Interventional
Phase 2
Beijing, Beijing/Beijing, 100010, China
Meng-Tong Zang, MD
CONTACT
Xiao-Hui Zhang, Professor
CONTACT
This is a parallel-group, multicenter, randomized controlled trial of 48 pregnancies with protein S deficiency in China. Patients are randomized into three groups to receive enoxaparin combined with aspirin, aspirin alone and no intervention. The primary outcome measure is livebirth rate.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Enoxaparin 4000 IU/day by subcutaneous injection at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
Other names: lovenox, clexane
Aspirin 75mg, orally, once daily at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
Other names: ASA
Time frame: From date of randomization until delivery, assessed up to 42 months
Incidents of livebirth
Time frame: From the start of study treatment to 6 weeks post-partum
D-Dimer in ng/ml, Protein S activity in %
Time frame: From the start of study treatment to 6 weeks post-partum
Maternal platelet count in 10^9/L, Number of haemorrhagic events, Number of cases of skin reactions at injection site
Time frame: up to 37 weeks
early miscarriage (until 12 weeks of gestation), late miscarriage (12-28 weeks of gestation), premature livebirths (28-37 weeks of gestation)
Time frame: after the delivery (an expected average of one month)
Neonatal weight in grams, Neonatal length in centimetres, Apgar 1-minute, 5-minute, 10-minute scores in scores, Number of neonatal complications
Time frame: up to 6 weeks post-partum
Incidents of pre-eclampsia, intrauterine growth retardation, placental abruption, and intrauterine foetal death, etc.
Time frame: From the start of study treatment to 6 weeks post-partum
thrombosis/thromboembolism
Contact information is provided by the study sponsor or research team.
Meng-Tong Zang, MD
CONTACT
Xiao-Hui Zhang, Professor
CONTACT
Peking University People's Hospital
Other
A Multicenter, Open-label, Randomized, Controlled, Phase 2 Trial Evaluating Whether Low Molecular Heparin Could Improve Pregnancy Outcomes With Protein S Deficiency
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07707115
Behavior, Bias, Implicit
Salt Lake City, Utah, United States
View Trial DetailsNCT07556913
Bile Duct Diseases, Biliary Tract Diseases
View Trial DetailsNCT06069856
Pregnancy Related
View Trial DetailsNCT07548528
Pregnancy Related
Malatya, Turkey (Türkiye)
View Trial Details